These data suggest that pioglitazone promotes mitochondrial function and an anti-oxidant effect in MSCs against a CKD-induced pathophysiological condition through PGC-1α-PrPC signal transduction. The gene discussed is PPARGC1A; the disease is chronic kidney disease.